CRMD
CorMedix Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.38
+1.65%Year over year
Reported trailing growth
- Revenue
- +280.5%
- EBITDA
- +378.1%
- EBIT
- +340.1%
- EPS
- +207.9%
- Free cash flow
- +727.7%
- Operating cash flow
- +733.6%
Forward estimates
Based on analyst estimates
- Revenue
- -41.1%
- EBITDA
- -80.5%
- EPS
- —
Three-year CAGR
- Revenue
- +1582.8%
- EBITDA
- +981.8%
- EBIT
- +771.6%
- Net income
- +1009.4%
- EPS
- +850.0%
- Free cash flow
- +440.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026